Gilead science acquired new technology of developing HIV treatment drugs

Source: nai500 2016-08-13 Gilead Science Co., Ltd of the United States and genmab of Denmark signed a technical license agreement for bispecific antibody According to the agreement, Gilead science will be granted an exclusive license to use the gemab platform to develop HIV treatment drugs, as well as an option to acquire another exclusive license for the technology As a condition, Gilead science will make an advance payment of US $5 million (EUR 4.5 million) to genmab and commit to making milestone payments of up to US $277 million If HIV treatment drugs are successfully marketed, genmab will also receive a royalty per unit Two years ago, Gilead science contacted genmab's Bi specific platform through research cooperation At the time, however, Gilead science did not disclose genmab's identity Through exposure to the bispecific antibody platform, Gilead science has strengthened its strength in the field of HIV research The National Institutes of health, Rockefeller University and Duke University are all actively studying HIV treatment methods The Duke team has teamed up with Johnson & Johnson's Biosciences company macrogenomics Both the National Institutes of health and macrogenics research projects involve bispecificity related to HIV protein and CD3 receptor At the same time, starting from these two goals will enable the bispecific to gather "killer" T cells and HIV infected cells, so that the immune system can attack the virus The Rockefeller University team is studying the mechanisms involved in HIV-1 envelope glycoprotein The deal reflects Gilead science's interest in bispecific technology, which is being taken seriously in the field of HIV As we all know, in recent years, hepatitis C drugs have created the myth of Gilead science company However, last year's HIV licensing business also contributed nearly $10 billion in sales to the company If a licensing agreement can also be reached for the bispecific technology being developed by Gilead science, genmab will also add new sources of revenue Genmab, headquartered in Copenhagen, Denmark, has signed licensing agreements with the company for bispecific antibody platforms, including Johnson & Johnson, Novartis, Novo Nordisk and Gilead science In order to comply with the latest agreement with Gilead science, genmab needs to abandon most of its previous deals, but it is also expected to generate net income for the company in the future English source: